Literature DB >> 25253610

[ESSENCE gathers the diagnoses into a whole].

Christopher Gillberg1.   

Abstract

Co-existence of attention-deficit/hyperactivity disorder, oppositional defiant disorder, tic disorders, developmental coordination disorder, language disorder, learning problems, and autism spectrum disorder and sharing of symptoms across disorders, contribute to the typical clinical presentation in child psychiatry as well as in developmental medicine. The acronym ESSENCE refers to Early Symptomatic Syndromes Eliciting Neurodevelopmental Clinical Examinations. Affected children are brought for clinical assessment because of impairing symptoms that raise concern before the age of about 5 years in general development, communication and language, social inter-relatedness, motor coordination, attention, activity, behaviour, mood, and/or sleep. Such children are usually in need of a range of expert assessments, but a holistic approach is rarely taken from the start. Major problems in at least one ESSENCE domain before 5 years of age predict poor mental health later in life. Expert ESSENCE centres for assessment, habilitation and treatment of these children are needed.

Entities:  

Mesh:

Year:  2014        PMID: 25253610

Source DB:  PubMed          Journal:  Lakartidningen        ISSN: 0023-7205


  3 in total

1.  Using the PDD Behavior Inventory as a Level 2 Screener: A Classification and Regression Trees Analysis.

Authors:  Ira L Cohen; Xudong Liu; Melissa Hudson; Jennifer Gillis; Rachel N S Cavalari; Raymond G Romanczyk; Bernard Z Karmel; Judith M Gardner
Journal:  J Autism Dev Disord       Date:  2016-09

2.  Boys with Asperger Syndrome Grow Up: Psychiatric and Neurodevelopmental Disorders 20 Years After Initial Diagnosis.

Authors:  I Carina Gillberg; Adam Helles; Eva Billstedt; Christopher Gillberg
Journal:  J Autism Dev Disord       Date:  2016-01

3.  Health, functionality, and social support in families with a child with a neurodevelopmental disorder - a pilot study.

Authors:  Diana Cavonius-Rintahaka; Anna Liisa Aho; Arja Voutilainen; Eva Billstedt; Christopher Gillberg
Journal:  Neuropsychiatr Dis Treat       Date:  2019-05-08       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.